Alle Studien
Einschreibung auf EinladungBEOBACHTEND

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

This important study is designed for adult men in the UK living with haemophilia B. It's a long-term follow-up for those who previously took part in earlier studies (CSL222_2001 or CSL222_3001) where they received a gene therapy treatment called etranacogene dezaparvovec. The main purpose is to see how safe the treatment remains over many years and how effective it continues to be in managing their haemophilia B. By carefully monitoring participants, researchers hope to gain a better understanding of the lasting effects of this innovative treatment, which could ultimately help improve future care for people with this condition.

Auf einen Blick

Status
Einschreibung auf Einladung
Sponsor
CSL Behring
Einschreibeziel
56
Starten
30. Aug 2023
Geschätzte Fertigstellung
23 Mar 2035

Worum geht es in dieser Studie?

This study is a follow-up for adult men with haemophilia B who have already received a special gene therapy. Haemophilia B is a lifelong bleeding disorder where your blood doesn't clot properly due to a missing or faulty ‘Factor IX’ protein. Gene therapy like etranacogene dezaparvovec aims to provide instructions to your body to make this missing protein, potentially reducing bleeding episodes.

This particular study isn't offering new treatment; instead, it's looking at the long-term effects for people who have already had this gene therapy. Researchers want to understand if the treatment continues to be safe over many years and if it keeps working effectively to help manage haemophilia B. This is really important because gene therapies are relatively new, and understanding their long-term impact helps doctors and scientists make informed decisions about their wider use.

By carefully checking on the health and progress of these participants, the study contributes valuable information. It helps build a bigger picture of how this treatment works in the real world, beyond the initial trials. This knowledge is crucial for advancing our understanding of haemophilia B and developing even better therapies in the future.

Wichtige Erkenntnisse

  • This is a long-term follow-up study for men with haemophilia B.
  • Participants have already received a gene therapy called etranacogene dezaparvovec.
  • The study aims to understand the long-term safety and effectiveness of the treatment.
  • No new medication is given; it involves regular monitoring and health checks.
  • Your participation helps improve future care for haemophilia B patients.

Wer könnte berechtigt sein?

To be considered for this study, you must be an adult male who previously participated in one of the original treatment trials for etranacogene dezaparvovec – specifically, study CSL222_2001 or study CSL222_3001.

Additionally, you must have either fully completed your participation in one of those earlier studies, or at least five years must have passed since you received the etranacogene dezaparvovec gene therapy in one of those trials.

There are no other specific reasons listed that would prevent you from joining this follow-up study, provided you meet the criteria above.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am an adult male (aged 18 or over).
  2. I was previously treated with etranacogene dezaparvovec (CSL222) in study CSL222_2001 or CSL222_3001.
  3. I completed my participation in one of those earlier studies.
  4. OR at least 5 years have passed since I received the CSL222 treatment.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you'll be regularly monitored by a medical team. This will involve scheduled visits to the clinic where you'll have various health checks. These typically include blood tests to measure your Factor IX levels and check your general health, physical examinations, and questions about any bleeding episodes or your overall well-being. You won't be receiving new medication as part of this study; it's purely for observation. The total duration of your participation will depend on how long ago you received the gene therapy, as the study aims to track participants for many years after their initial treatment.

Potenzielle Risiken und Vorteile

Participating in this study offers a potential benefit of ongoing, close medical supervision of your health, particularly regarding your haemophilia B and the effects of the gene therapy you received. You would also be contributing valuable information that could help others living with haemophilia B in the future. As you have already received the treatment, the direct risks from the treatment itself are not new, but any long-term monitoring study involves regular clinic visits, which can be time-consuming, and blood tests, which carry minimal risks like bruising. You are free to withdraw from the study at any time without needing to give a reason, and this will not affect your usual medical care.

Locations (28)

  • 10-15 Phoenix Childrens Hospital
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten
  • 10-14 Arkansas Children's Hospital - Pharmacology
    Verifizierte Postleitzahl
    Little Rock, Vereinigte Staaten
  • 10-22 Orthopaedic Institute for Children
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • 10-21 Children's Hospital of Los Angeles
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • 10-63 UC Davis Medical Center
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • 10-12 University of California, San Diego (UCSD)
    Verifizierte Postleitzahl
    San Diego, Vereinigte Staaten
  • 10-25 University of Colorado Denver
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten
  • 10-19 University of South Florida
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten
  • 10-10 University of Michigan Medical Center
    Verifizierte Postleitzahl
    Ann Arbor, Vereinigte Staaten
  • 10-16 University of North Carolina at Chapel Hill
    Verifizierte Postleitzahl
    Chapel Hill, United States
  • 10-18 Oregon Health & Science University
    Verifizierte Postleitzahl
    Portland, Vereinigte Staaten
  • 10-20 Vanderbilt University Medical Center
    Verifizierte Postleitzahl
    Nashville, Vereinigte Staaten

Häufige Fragen

Was ist Hämophilie B?

Haemophilia B is an inherited bleeding disorder where your blood doesn't clot properly due to a missing or faulty Factor IX protein, leading to prolonged bleeding.

What is etranacogene dezaparvovec?

It's a gene therapy treatment that aims to help your body produce the missing Factor IX protein, which can reduce bleeding episodes in people with haemophilia B.

Am I receiving new treatment in this study?

No, this study is a follow-up. You won't receive new treatment; it's for monitoring those who previously had the gene therapy.

Wie lange muss ich an der Studie teilnehmen?

The study aims for long-term follow-up; the duration for you will depend on when you received your initial gene therapy treatment in the parent studies.

What is the purpose of this long-term study?

The main purpose is to understand the long-term safety and effectiveness of etranacogene dezaparvovec gene therapy for men with haemophilia B.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Long-term Follow-up Study of Male Adults With Hemophilia B P… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.